KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Inventory (2016 - 2026)

NovoCure's Inventory history spans 13 years, with the latest figure at $43.5 million for Q1 2026.

  • On a quarterly basis, Inventory rose 10.11% to $43.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $43.5 million, a 10.11% increase, with the full-year FY2025 number at $41.1 million, up 17.17% from a year prior.
  • Inventory hit $43.5 million in Q1 2026 for NovoCure, up from $41.1 million in the prior quarter.
  • Over the last five years, Inventory for NVCR hit a ceiling of $43.5 million in Q1 2026 and a floor of $26.8 million in Q3 2022.
  • Historically, Inventory has averaged $36.2 million across 5 years, with a median of $38.2 million in 2023.
  • Biggest five-year swings in Inventory: surged 37.38% in 2023 and later dropped 8.04% in 2024.
  • Tracing NVCR's Inventory over 5 years: stood at $29.4 million in 2022, then increased by 29.87% to $38.2 million in 2023, then decreased by 8.04% to $35.1 million in 2024, then increased by 17.17% to $41.1 million in 2025, then grew by 5.71% to $43.5 million in 2026.
  • Business Quant data shows Inventory for NVCR at $43.5 million in Q1 2026, $41.1 million in Q4 2025, and $39.1 million in Q3 2025.